search icon
search icon
Flag Arrow Down
Română
Română
Magyar
Magyar
English
English
Français
Français
Deutsch
Deutsch
Italiano
Italiano
Español
Español
Русский
Русский
日本語
日本語
中国人
中国人

Change Language

arrow down
  • Română
    Română
  • Magyar
    Magyar
  • English
    English
  • Français
    Français
  • Deutsch
    Deutsch
  • Italiano
    Italiano
  • Español
    Español
  • Русский
    Русский
  • 日本語
    日本語
  • 中国人
    中国人
Sections
  • News
  • Exclusive
  • INSCOP Surveys
  • Podcast
  • EU
  • Diaspora
  • Republic of Moldova
  • Politics
  • Economy
  • Current Affairs
  • International
  • Sport
  • Health
  • Education
  • IT&C knowledge
  • Arts & Lifestyle
  • Opinions
  • Elections 2025
  • Environment
About Us
Contact
Privacy policy
Terms and conditions
Quickly scroll through news digests and see how they are covered in different publications!
  • News
  • Exclusive
    • INSCOP Surveys
    • Podcast
    • EU
    • Diaspora
    • Republic of Moldova
    • Politics
    • Economy
    • Current Affairs
    • International
    • Sport
    • Health
    • Education
    • IT&C knowledge
    • Arts & Lifestyle
    • Opinions
    • Elections 2025
    • Environment
130 new news items in the last 24 hours
  1. Home
  2. International

Novo Nordisk's earnings fell by 20% following warnings about price pressures in 2026

Cristiana Dida
whatsapp
facebook
linkedin
x
copy-link copy-link
4 February 2026, 12:22
main event image
International
Foto: Facebook/ Novo Nordisk
google-preference

Always see our news on Google

Shares of Novo Nordisk, known for the medications Ozempic and Wegovy, have dropped by up to 20% after the company announced it would face unprecedented pricing pressures in 2026, which will lead to a sales decline of up to 13% this year.


This negative estimate is influenced by initiatives to reduce prices in the U.S. and increasing competition in the weight loss treatment market. CEO Mike Doustdar mentioned that although the financial impact will be painful, it is an investment in the future. The drop in shares has wiped out over 40 billion euros from the company's market capitalization. Additionally, Novo Nordisk is facing increasing competition and issues related to 'copycat' drugs. However, strong sales of the new oral treatment Wegovy offer a glimmer of hope, with weekly prescriptions exceeding expectations.

Sources

sursa imagine
Hot News
Producătorul medicamentelor Ozempic și Wegovy s-a prăbușit pe bursă după un avertisment de presiuni „fără precedent” asupra prețurilor
sursa imagine
The Guardian EU
Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

Latest News

18:19

Eurostat shows employment gaps of at least 18 percentage points between men and women in five regions of Romania

18:19

Two ANAF employees from Argeș were detained after allegedly asking for 40,000 lei to conceal tax irregularities

18:09

Police in Argeș found weapons, ammunition and pyrotechnic articles during 30 raids carried out in several localities

18:00

UniCredit pledges to keep Commerzbank’s headquarters and support German companies in order to gain control of the bank

17:49

Avocata generală a CJUE consideră că Facebook nu poate fi numit gratuit când accesul presupune folosirea comercială a datelor personale

See more news

NEWS ON THE SAME TOPICS

event image
IT&C knowledge
Novo collaborates with Anthropic to use artificial intelligence in the research and development of new medicines
event image
Economy
PepsiCo cuts its 2026 profit forecast and announces new cost-cutting measures
event image
International
AI companies and chipmakers lose more than $1 trillion amid concerns over financing
event image
IT&C knowledge
The 2026 Nobel season opens today: Research on satiety hormones and weight-loss medications are the leading favorites for Medicine
event image
International
Germany will provide €400 million to maintain Sanofi’s insulin production and reduce the risk of shortages in Europe
event image
Economy
Volkswagen announces exceptional costs of 10 billion euros and reduces its estimated profit margin for 2026 to no more than 1%
app preview
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
app preview app preview
new nordisk actions drop falling sales USA prices

Editor’s Recommendations

main event image
INSCOP Surveys
9 hours ago

November 2026: Informat.ro – INSCOP Research BAROMETER, 15th Edition – Chapter X: Temporary Restriction of Access to Online Platforms

main event image
Exclusive
1 hour ago

EXCLUSIVE Ranking of companies in relevant online sources in Romania: Nvidia dominates company visibility. Finance and investments lead the economic agenda

main event image
Opinions
7 hours ago

Andrei Pleșu: What Our Ministers Were and What They Have Become

main event image
Exclusive
8 hours ago

EXCLUSIVE The top domestic political topics trending over the past week / The Lyrica shortage crisis, Marian Neacșu’s new responsibilities, and debates over administrative reform

app preview
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
app preview
app store badge google play badge
  • News
  • Exclusive
  • INSCOP Surveys
  • Podcast
  • EU
  • Diaspora
  • Republic of Moldova
  • Politics
  • Economy
  • Current Affairs
  • International
  • Sport
  • Health
  • Education
  • IT&C knowledge
  • Arts & Lifestyle
  • Opinions
  • Elections 2025
  • Environment
  • About Us
  • Contact
Privacy policy
Cookies Policy
Terms and conditions
Open source licenses
All rights reserved Strategic Media Team SRL

Technology in partnership with

anpc-sal anpc-sol